Prof. Dr. med. Petr Hrúz
Chefarzt Stv. Gastroenterologie/Hepatologie
Leiter Standort Claraspital
Portrait
Lebenslauf
04/2023
Stellvertretender Chefarzt Gastroenterologie/Hepatologie, Clarunis Universitäres Bauchzentrum Basel
11/2019
Ernennung zum Titularprofessor, Universität Basel
seit 2019
Leitender Arzt Gastroenterologie/Hepatologie, Clarunis Universitäres Bauchzentrum Basel/
Standort Universitätsspital Basel
02/2015
Leitender Arzt Gastroenterologie/Hepatologie, Universitätsspital Basel
01/2010-01/2015
Resident and Senior Physician in Gastroenterology, Department of Gastroenterology and Hepatology, University Hospital of Basel
June 2012
FMH Gastroenterology and Hepatology
03/2007-12/2009
Post-Doc Research Fellowship University California San Diego, La Jolla, School of Medicine, Department of Gastroenterology; USA
March 2007
FMH Internal Medicine
04/2004-12/2006
Resident in Internal Medicine, University Polyclinic and Clinic A University Hospital of Basel
11/2002-03/2004
Research Fellow; Postgraduate Course for Experimental Medicine:
Department of Clinical Pharmacology and Toxicology, Department of Gastroenterology, University Hospital of Basel
04/2002-10/2002
Research Fellow; Postgraduate Course for Experimental Medicine, University Hospital of Zürich
09/2000-03/2002
Resident in Internal Medicine, Clinic B, University Hospital of Basel
03/1999-08/2000
Resident in Urology, University Clinic of Urology, Inselspital Bern
01/1998-02/1999
Resident in Psychiatry, Psychiatric University Clinic Basel
1991-1997
Study of Medicine, University of Basel
Mitgliedschaften
- American Gastroenterological Association (AGA)
- Foederatio Medicorum Helveticorum (FMH)
- Schweizerische Gesellschaft für Gastroenterologie (SGG)
- Swiss Research and Communication Network on Inflammatory Bowel Disease (IBDnet)
Publikationen
- Kaymak, T, Kaya B, Wuggenig P, Nuciforo S, Göldi A, Oswald F, Roux J, Noti M, Melhem H, Hrúz P, Niess JH: IL-20 subfamily cytokines impair the oesophageal epithelial barrier by diminishing filaggrin in eosinophilic oesophagitis. Gut, 2022.
- Muller A, Bilger SS, Goldi A, Meinlschmidt G, Rueter F, Kappes A, Hruz P, Meier CA, Niess JH: The IBD-Control questionnaire: German translation and validation of the standardized questionnaire for Patient Reported Outcome Measurement in inflammatory bowel disease. Z Gastroenterol. 2O21.
- Kaymak T, Hrúz P, Niess jH: Immune system and microbiome in the esophagus: implications for understanding inflammatory diseases. Febs j, 2022. 289(16): p. 4758-4772.
- Sutter M, Hrúz P, Niess JH: High Serum Creatine Kinase Levels in Infliximab and Vedolizumab-Treated Inflammatory Bowel Disease Patients. Inflamm Intest Dis. 2O21: 6: 165-174.
- Rohm TV, Fuchs R, Müller RL, Keller L, Baumann Z, Bosch AJT, Schneider R, Labes D, Langer I, Pilz JB, Niess JH, Delko T, Hrúz P, Cavelti-Weder C: Obesity in Humans Is Characterized by Gut Inflammation as Shown by Pro-Inflammatory Intestinal Macrophage Accumulation. 2021: Frontiers in immunology 12: 668654.
- Manzini R, Schwarzfischer M, Atrott K, Laimbacher A, Lang S, Wawrzyniak M, Rickenbacher A, Turina M, Hruz P, Lissner D, Siegmund B, Rogler G, Scharl M, Spalinger MR: Combination of Vedolizumab With Tacrolimus Is More Efficient Than Vedolizumab Alone in the Treatment of Experimental Colitis. 2021: Inflamm Bowel Dis. 27: 1986–1998.
- Mader O, Juillerat P, Biedermann L, Michetti P, Hrúz P, Pittet V, Rogler G, Zahnd-Straumann N, Seibold F: Factors influencing the outcome of vedolizumab treatment: Real-life data with objective outcome measurements. 2021: United European Gastroenterol J. 9: 398–406.
- Biedermann L, Straumann A, Hrúz P: Defer No Time, Delays Have Dangerous Ends (William Shakespeare). 2021: Gastroenterology 161: 42–44.
- Grandinetti T, Biedermann L, Bussmann C, Straumann A, Hruz P. Eosinophilic Gastroenteritis: Clinical Manifestation, Natural Course and Evaluation of Treatment with Corticosteroids and Vedolizumab. Dig Dis Sci. 2019 Apr 13. doi: 10.1007/s10620-019-05617-3.
- Bengs S, Becker E, Busenhart P, Spalinger MR, Raselli T, Kasper S, Lang S, Atrott K, Mamie C, Vavricka SR, von Boehmer L, Knuth A, Tuomisto A, Mäkinen MJ, Hruz P, Turina M, Rickenbacher A, Petrowsky H, Weber A, Frei P, Halama M, Jenkins G, Sheppard D, Croner RS, Christoph J, Britzen-Laurent N, Naschberger E, Schellerer V, Stürzl M, Fried M, Rogler G, Scharl M.β6 -integrin serves as a novel serum tumor marker for colorectal carcinoma. Int J Cancer. 2019 Jan 17.
- Fuchs S, Sawas N, Staedler N, Schubert DA, D'Andrea A, Zeiser R, Piali L, Hruz P*, Frei AP*. High-dimensional single-cell proteomics analysisidentifies immune checkpoint signatures and therapeutic targets in ulcerative colitis. Eur. J. Immunol. 2019. 49: 462–475
- Schmaler M, Colone A, Spagnuolo J, Zimmermann M, Lepore M, Kalinichenko A, Bhatia S, Cottier F, Rutishauser T, Pavelka N, Egli A, Azzali E, Pieroni M, Costantino G, Hruz P, Sauer U, Mori L, De Libero G. Modulation of bacterial metabolism by the microenvironment controls MAIT cell stimulation. Mucosal Immunol 2018; 11:1060-70
- Safroneeva E, Saner C, Rossel JB, Golay D, Pittet V, Godat S, Diem S, Aepli P, Sawatzki M, Borovicka J, Burgmann K, Juillerat P, Netzer P, Sendensky A, Hruz P, Girardin M, Biedermann L, Greuter T, Vavricka S, Michetti P, Mueller C, Straumann A, Schoepfer A.M. on behalf of the Swiss EoE Cohort Study Group. Cohort Profile: The Swiss Eosinophilic Esophagitis Cohort Study (SEECS). Inflamm Intest Dis 2018: published online January 31st 2018
- Kaymak T, Moriconi F, Niess JH, Beglinger C, Hruz P. Low discontinuation rate of Infliximab treatment in steroid-dependent/refractory Crohn’s disease patients. Inflamm Intest Dis 2018: published online February 21st 2018
- Steinert A, Linas I, Kaya B, Ibrahim M, Schlitzer A, Hruz P, Radulovic K, Terracciano L, Macpherson AJ, Niess JH. The Stimulation of Macrophages with TLR Ligands Supports Increased IL-19 Expression in Inflammatory Bowel Disease Patients and in Colitis Models. J Immunol. 2017;199:2507-84
- Navarini AA*, Hruz P*, Berger CT, Hou TZ, Schwab C, Gabrysch A, Higgins R, Frede N, Padberg Sgier BC, Kämpe O, Burgener AV, Marquardsen F, Baldin F, Bigler M, Kistner A, Jauch A, Bignucolo O, Meyer B, Meienberg F, Mehling M, Jeker LT, Heijnen I, Daikeler TD, Gebbers JO, Grimbacher B, Sansom DM, Jeker R, Hess C, Recher M. Vedolizumab as a successful treatment of CTLA-4-associated autoimmune enterocolitis. J Allergy Clin Immunol. Mar;139(3):1043-1046 * contributed equally
- Straumann A, Blanchard C, Radonjic-Hoesli S, Bussmann Ch, Hruz P, Safroneeva E, Simon D, Schoepfer AM, Simon HU. A new eosinophilic esophagitis (EoE)-like disease without tissue eosinophilia found in EoE families. Allergy 2016;71:889-900
- Miehlke S*, Hruz P*, Vieth M, Bussmann C, von Arnim U, Bajbouj M, Schlag C, Madisch A, Fibbe C, Wittenburg H, Allescher HD, Reinshagen M, Schubert S, Tack J, Müller M, Krummenerl P, Arts J, Mueller R, Dilger K, Greinwald R, Straumann A. A randomised, double-blind trial comparing budesonide formulations and dosages for short-term treatment of eosinophilic oesophagitis. Gut 2016;65:390-9 * contributed equally
- Kahn J, Bussmann C, Beglinger C, Straumann A, Hruz P. Exercise-induced chest pain: an atypical manifestation of Eosinophilic Esophagitis. Am J Med 2015; 128:196-9
- Mecklenburg I, Reznik D, Fasler-Kan E, Drewe J, Beglinger C, Hruz P. Serum hepcidin concentrations correlate with ferritin in patients with inflammatory bowel disease. J Crohns Colitis. 2014; 8(11):1392-7
Reviews
- Hruz P, Straumann A Chapter 3: Epidemiology of Eosinophilic Esophagitis in Adults. C.A. Liacouras and J.E. Markowitz (eds.), Eosinophilic Esophagitis, Clinical Gastroenterology, 2012, 25-38 (Book chapter)
- Hruz P. Epidemiology of eosinophilic esophagitis. Dig Dis. 2014;32:40-7 (Review)
- Hruz P. Epidemiology of Eosinophilic Esophagitis. Unimed 2014 (Book chapter)
- Niess JH, Hruz P, Kaymak T. The Interleukin-20 Cytokines in Intestinal Diseases. Front Immunol. 2018 Jun 18;9:1373.
- Niess JH, Kaymak T, Hruz P. The Role of the Exposome in the Emergence of Chronic Inflammatory Bowel Diseases. Ther Umsch. 2019 Jan;75:261-270.